INMB

INmune Bio Inc.

9.33
USD
0.32%
9.33
USD
0.32%
4.63 30.37
52 weeks
52 weeks

Mkt Cap 166.48M

Shares Out 17.84M

Chat
Send me real-time posts from this site at my email

INmune Bio down 22% on Alzheimer's candidate mid-stage trial hold

Shares of INmune Bio (NASDAQ:INMB) are down 22% in Tuesday morning trading following the company's announcement after Monday's closing bell that the U.S. FDA has placed on hold starting a phase 2 trial Alzheimer's disease candidate XPro1595. The FDA also requested additional details about XPro1595's chemistry manufacturing and controls. B Riley analyst Mayank Mamtani responded to the development by downgrading INmune (INMB) to neutral from buy and halving the price target to $7 (~4% downside based on Monday's close) Mamtani noted that there is "limited visibility to the required corrective measures and magnitude of potential delay." While maintaining a buy rating, BTIG cut its price target to $14 from $31 (~93% upside). In April, Seeking Alpha contributor Terry Chrisomalis called INmune a "great speculative biotech play."

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue